Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue, net:
Core companion animal health	$ 15,649	$ 16,580
Other vaccines, pharmaceuticals and products	3,330	2,595
Total revenue, net	18,979	19,175
Cost of revenue	11,177	10,252
Gross profit	7,802	8,923
Operating expenses:
Selling and marketing	5,125	4,888
Research and development	390	334
General and administrative	2,969	2,619
Total operating expenses	8,484	7,841
Operating income (loss)	(682)	1,082
Interest and other expense, net	(11)	142
Income (loss) before income taxes	(671)	940
Current tax expense	6	48
Deferred tax expense (benefit)	(325)	308
Total income tax expense (benefit)	(319)	356
Net income (loss)	(352)	584
Net (income) loss attributable to non-controlling interest	34	0
Net income (loss) attributable to Heska Corporation	$ (386)	$ 584
Basic net income (loss) per share attributable to Heska Corporation	$ (0.07)	$ 0.11
Diluted net income (loss) per share attributable to Heska Corporation	$ (0.07)	$ 0.11
Weighted average outstanding shares used to compute basic net income (loss) per share attributable to Heska Corp.	5,547	5,264
Weighted average outstanding shares used to compute diluted net income (loss) per share attributable to Heska Corp	5,547	5,434